To filter by categories, simply select the relevant categories and/or statuses and click "submit" (without entering any text into the search field).
To search by Protocol name, simply enter it into the search box and click "submit".
*NOTE* if there are categories that have no protocols attached, they will not show up as a checkbox for filtering. For example, if "Head and Neck" is not available as a disease category checkbox selection, there are no protocols that have that disease category assigned.
Primary Category:
Treatment Protocols
Disease Category:
Brain
Status:
Open
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations
NCT#02523014
A071401 Cohorts NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) are closed to new patient registration (Step 1) to abemaciclib cohort, effective October 3, 2022.
Primary Category:
Treatment Protocols
Disease Category:
Brain
Status:
Open
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
NCT#03224767
Primary Category:
Treatment Protocols
Disease Category:
Brain, Brain Metastatic, Molecular Profiling
Status:
Open
Genomically-Guided Treatment Trial in Brain Metastases
NCT#03994796
Primary Category:
Treatment Protocols
Disease Category:
Brain
Status:
Open
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma
NCT#04145115
Primary Category:
Radiation Oncology
Disease Category:
Brain, Brain Metastatic
Status:
Open
A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases
Eligible for screening study DCP 001
For CCTG CE.7, please credit ALLIANCE all accruals.
NCT#03550391
CCTG CE.7 has reopened with Amendment 1 to resume patient accrual at your center, your site will be required to provide confirmation of HA-WBRT credentialing and approval by IROC.
Protocol Consent Schema Eligibility & Calendar
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Brain
Status:
Open
(CODEL) Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Eligible for screening study DCP 001
NCT#00887146
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Brain
Status:
Open
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Eligible for screening study DCP 001
NCT#03180268
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Brain
Status:
Temporarily Closed
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
NCT#04729959
BN010 is temporarily closed to accrual to Safety Run-In/Dose Level 3, effective April 17, 2023.
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Brain, Brain Metastatic
Status:
Open
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
NCT#05438212
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Brain, Lung, Lung - Small Cell
Status:
Open
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Eligible for screening study DCP 001
NCT#04804644
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Status:
Open
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Eligible for screening study DCP 001
NCT#04457596
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Adjuvant Breast, Breast
Status:
Temporarily Closed
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Eligible for screening study DCP 001
NCT#04379570
A191901 is temporarily closed to accrual, effective November 16, 2022.
A191901 is permanently closed to accrual of non-Black women over 50, effective February 25, 2022 at 4:30pm (ET)
A191901 is permanently closed to accrual of non-Black women, effective April 15, 2022 at 4:30pm (ET)
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Adjuvant Breast, Breast
Status:
Open
Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial
NCT#04989504
Eligible for screening study DCP 001
A221803 has reached the planned number of participating sites for the trial and are not adding anymore as of 10/03/2022. If you haven’t already received a Site Approval Letter from study, your site will not be able to participate at this time. If additional slots are opened to sites in the future study will let us know.
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast
Status:
Open
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Limited institution study: open only to Saint Alphonsus Health System.
NCT#03233191
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
Status:
Open
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
EA1181 ER-Negative Cohort is closed to accrual, effective May 25, 2023.
EA1181 HER2+/ER+ Subset with tumor size 2.1-3.0 cm and node negative is closed to accrual, effective July 27, 2022.
NCT#04266249
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Open
FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
NCT#04316117
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
New, Open
Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial
NCT#05554354
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast
Status:
Open
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT#04852887
Eligible for screening study DCP 001
BR007, HRQOL Sub-study, is closed to accrual, effective April 24, 2023.
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Status:
Open
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Eligible for screening study DCP 001
For CCTG MA.39, please credit NRG all accruals.
CCTG MA.39-Optional Questionnaire Component is closed to accrual effective August 2, 2022
NCT#03488693
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Open
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Eligible for screening study DCP 001
NCT#03418961
S1501, Arm 3 is permanently closed to accrual, effective July 29, 2021, at 11:59pm Pacific Time.
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Open
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NCT#03723928
Eligible for screening study DCP 001
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Status:
Open
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
NCT#03598257
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Open
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
NCT#04647916
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Status:
New, Open
A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)
NCT#05568472
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Cancer Care Delivery
Disease Category:
Cancer Care Delivery
Status:
Open
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Eligible for screening study DCP 001
NCT#04960787
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Neuroendocrine, Pancreatic
Status:
Open
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
NCT#03375320
Eligible for screening study DCP 001
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Status:
New, Open
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
NCT#05673148
Eligible for screening study DCP 001
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Anal, Gastrointestinal
Status:
Open
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
Eligible for screening study DCP 001
NCT#04444921
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Anal, Gastrointestinal
Status:
Open
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
NCT#04166318
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Esophageal, Esophageal Metastatic, Gastrointestinal, Stomach, Stomach Metastatic
Status:
Open
A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
NCT#04248452
Eligible for screening study DCP 001
EA2183 is reopened to accrual with the implementation of Amendment 2, effective April 5, 2022
Primary Category:
Surgical Protocols, Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic Metastatic
Status:
Open
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
NCT#04233866
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Rectal
Status:
Temporarily Closed
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
NCT#04751370
EA2201 is temporarily closed to accrual, effective May 9, 2023.
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Status:
Open
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Eligible for screening study DCP 001
NRG GI004 reopened to accrual effective January, 29, 2021.
NCT#02997228
Site Delegation of Tasks Log required prior to registration of any patients.Primary Category:
Treatment Protocols
Disease Category:
Colon, Gastrointestinal
Status:
Open
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
NCT#04068103
GI005 is reopened upon implementation of Amendment 1, effective June 15, 2021.
Primary Category:
Treatment Protocols
Disease Category:
Colon
Status:
Open
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
NCT#05174169
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Small Bowel
Status:
Open
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
NCT#04205968
Primary Category:
Treatment Protocols
Disease Category:
Pancreatic, Pancreatic Metastatic
Status:
Open
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
NCT#04548752
S2001 is reopened to accrual with the implementation of Revision 4, effective April 18, 2023.
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Rectal, Rectal Metastatic
Status:
Open
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
NCT#05308446
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Status:
Open
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
NCT#03609216
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary, Prostate, Renal
Status:
Open
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
NCT#03866382
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal, Renal Metastatic
Status:
Open
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Eligible for screening study DCP 001
NCT#03793166
A031704 is reactivated to new patient registration (Step 1), effective March 26, 2021.
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Renal, Renal Metastatic
Status:
Open
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)
NCT#04071223
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Status:
Open
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
NCT#04164082
A031803 is reopened to accrual with implementation of Update 8, effective April 18, 2023.
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate Metastatic
Status:
Temporarily Closed
CASPAR – A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Eligible for screening study DCP 001
A031902 is temporarily suspended to new patient registration (OPEN Step 0), effective April 10, 2023.
A031902 is temporarily suspended to new patient registration (OPEN Step 2), effective May 10, 2023.
NCT#04455750
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate
Status:
Open
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
NCT#03697148
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Bladder, Genitourinary
Status:
Open
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
NCT#04216290
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate
Status:
Open
Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Eligible for screening study DCP 001
NCT#04423211
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Radiation Oncology
Disease Category:
Genitourinary, Prostate
Status:
Open
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (with Initial Phase I)
NCT#04037254
GU007 is reopened to accrual to phase I/dose level 3, effective March 24, 2023.
GU007 Phase II is not open to accrual as of January 27, 2022.
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
Status:
Open
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
NCT#04134260
Eligible for screening study DCP 001
GU008 is reopened to accrual upon implementation of Amendment 2, effective December 7, 2021.
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Prostate
Status:
Open
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Eligible for screening study DCP 001
Optional Imaging Sub Study is temporarily closed accrual, effective December 21, 2021
NCT#04513717
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Prostate
Status:
Open
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
NCT#05050084
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
Status:
Open
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
NCT#03678025
Eligible for screening study DCP 001
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Bladder, Genitourinary
Status:
Open
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
NCT#03775265
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary
Status:
Temporarily Closed
A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
S1937 is temporarily closed to accrual, effective 05/30/23 at 12:00pm PST.
Eligible for screening study DCP 001
NCT#04579224
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, GYN Other, Gynecologic, Ovarian, Ovarian Metastatic
Status:
New, Open
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
NCT#05554328
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Ovarian
Status:
Open
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Eligible for screening study DCP 001
NCT#04251052
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
Status:
Open
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer
NCT#03660826
GY012 is reopened to accrual, effective May 23, 2022.
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian, Ovarian Metastatic
Status:
Open
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Eligible for screening study DCP 001
NCT#04095364
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
GYN Other, Gynecologic
Status:
Open
Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial
NCT#05076942
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
Status:
Open
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
NCT#05256225
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Status:
Open
Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
NCT#02734537
Primary Category:
Treatment Protocols
Disease Category:
Head and Neck
Status:
Open
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
NCT#03811015
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Head and Neck
Status:
Open
Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a (and selected T4b) nasal and paranasal sinus squamous cell carcinoma (NPNSCC)
NCT#03493425
Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Status:
Open
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
NCT#04671667
EA3191 is reopened to accrual with the implementation of Addendum 6, effective April 18, 2023
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Radiation Oncology
Disease Category:
Head and Neck
Status:
Open
A Randomized Phase II/II Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Open to Phase II enrollment
NCT#03952585
HN005 is reopened to accrual, with implementation of Amendment 3, effective 06/06/23.
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Status:
Open
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
NCT#01810913
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Treatment Protocols
Disease Category:
Acute Lymphocytic Leukemia, Leukemia
Status:
Temporarily Closed
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
NCT#03150693
Eligible for screening study DCP 001
Temporary suspension effective May 24, 2022 due to Alliance DSMB review.
Confirmation of Tolerability Phase and slot reservation completed and study currently open to Phase III enrollment as of 06/12/2018. See Section 4.4 for registration and randomization instructions.
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia
Status:
Temporarily Closed
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
NCT#03701308
A041701, pre-registration (Step 0) is temporarily closed to accrual, effective November 19, 2021 at 4:30 PM ET.
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Chronic Myeloid Leukemia, Leukemia
Status:
Open
BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD
NCT#03516279
EA9171 is reopened to accrual with the implementation of Addendum 10, effective April 18, 2023
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Leukemia, Myelodysplastic Syndrome
Status:
Open
The National Myelodysplastic Syndromes (MDS) Study
NCT#02775383
Eligible for screening study DCP 001
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
Suspension to enrollment of new participants and follow-up research sample collection and shipment is lifted effective May 18, 2020, for NHLBI-MDS. Refer to memo dated March 27, 2020, on conducting remote follow-up data for enrolled participants.
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Lymphoma
Status:
Open
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Eligible for screening study DCP 001
NCT#04269902
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Status:
Open
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
(See required screening study ALLIANCE A151216)
NCT#04267848
A081801 is reopened to accrual with the implementation of Update 9, effective April 18, 2023.
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Status:
Open
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105 (closed), A081801, E4512, and EA5142 (closed).
Eligible for screening study DCP 001
Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.
NCT#02194738
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Status:
Open
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02201992
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Open
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
NCT#03191149
EA5162 is reopened to accrual, effective December 20, 2022.
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Open
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
NCT#03793179
Eligible for screening study DCP 001
EA5163 is reopened to accrual with the implementation of Addendum 6, effective April 18, 2023.
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Status:
Open
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Eligible for screening study DCP 001
NCT#04092283
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Open
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Eligible for screening study DCP 001
NCT#04181060
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell Metastatic
Status:
Open
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
NCT#04310007
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Brain, Lung, Lung - Small Cell
Status:
Open
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Eligible for screening study DCP 001
NCT#04804644
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Temporarily Closed
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
NCT#03137771
LU002 is temporarily closed to accrual, effective November 12, 2021.
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage
Status:
Open
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
NCT#04402788
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Open
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
NCT#03851445
Eligible for screening study DCP 001
Effective, June 30th, 2019, the sub-study S1400GEN is closed to accrual.
Primary Category:
Radiation Oncology
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage
Status:
Open
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Eligible for screening study DCP 001
NCT#04155034
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Open
A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
See Screening Protocol LUNGMAP
S1900E reopened to accrual effective May 26, 2021.
NCT#04625647
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell Metastatic
Status:
Open
A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
See Screening Protocol LUNGMAP
NCT#05364645
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell Metastatic
Status:
New, Open
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
See Screening Protocol LUNGMAP
NCT#05642572
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Status:
Open
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Eligible for screening study DCP 001
NCT#04214262
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung - Non-Small Cell
Status:
Open
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
NCT#04310020
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
New, Open
Pragmatica – Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT#05633602
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Neuroendocrine, Pancreatic
Status:
Open
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
NCT#03375320
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Status:
Temporarily Closed
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
NCT#03984448
A051701 is temporarily closed to accrual effective August 2, 2021.
A051701 accrual of patients with double expressing lymphoma (DEL) is temporarily halted effective August 2, 2021.
A051701 accrual of patients of all ages with double hit lymphoma (DHL) is temporarily halted effective September 28, 2020.
Primary Category:
Treatment Protocols
Disease Category:
Lymphoma, Non-Hodgkin Lymphoma
Status:
Open
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
NCT#04803201
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma
Status:
Open
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
NCT#03267433
Eligible for screening study DCP 001
Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Treatment Protocols
Disease Category:
Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Status:
Open
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
S1608 is reopened to accrual, effective March 10, 2023, at 12:00 pm Pacific Time.
NCT#03269669
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Lymphoma
Status:
Open
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Eligible for screening study DCP 001
NCT#04269902
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Treatment Protocols
Disease Category:
Brain, Brain Metastatic, Molecular Profiling
Status:
Open
Genomically-Guided Treatment Trial in Brain Metastases
NCT#03994796
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Status:
Open
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105 (closed), A081801, E4512, and EA5142 (closed).
Eligible for screening study DCP 001
Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.
NCT#02194738
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Status:
Open
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02201992
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
Effective today, July 18th, 2019, Subprotocol K2: Phase 2 is suspended due to the completion of accrual.
NCT#02465060
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
(See required screening study ECOG-ACRIN EAY131)
EAY131 Subprotocol M is temporarily closed to accrual, effective August 3, 2021
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy
(See required screening study ECOG-ACRIN EAY131)
Accrual to EAY131-Z1M is suspended, effective January 17,2023.
NCT#02465060
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Open
FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
NCT#04316117
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Status:
Open
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Eligible for screening study DCP 001
NCT#03937635
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Status:
Open
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Eligible for screening study DCP 001
NCT#04566328
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
New, Open
Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial
NCT#05554354
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Open
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Eligible for screening study DCP 001
NCT#03418961
S1501, Arm 3 is permanently closed to accrual, effective July 29, 2021, at 11:59pm Pacific Time.
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Open
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NCT#03723928
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Status:
Temporarily Closed
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Eligible for screening study DCP 001
Occupational Report & Pregnancy Report consent forms available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consents and for any questions.
S1803 is temporarily closed to accrual, effective March 29, 2023, at 12pm Pacific Time.
NCT#04071457
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Open
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
NCT#04647916
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Neuroendocrine, Pancreatic
Status:
Open
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
NCT#03375320
Eligible for screening study DCP 001
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Other
Status:
Temporarily Closed
Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
NCT#04936230
A032002 is temporarily closed to accrual, effective February 9, 2023.
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Other
Status:
Open
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Patients can be registered to DCP-001 up to 4 weeks after eligibility for and enrollment status to the trial for which the patient is being screened for has been determined. Participants may be screened for more than one clinical trial.
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
Status:
Open
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
EA1181 ER-Negative Cohort is closed to accrual, effective May 25, 2023.
EA1181 HER2+/ER+ Subset with tumor size 2.1-3.0 cm and node negative is closed to accrual, effective July 27, 2022.
NCT#04266249
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Treatment Protocols
Disease Category:
Skin
Status:
Open
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
NCT#03944941
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
Status:
Open
A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
NCT#05111574
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
Status:
Open
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
NCT#02339571
This protocol has additional training requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21
Primary Category:
Treatment Protocols
Disease Category:
Skin
Status:
Temporarily Closed
STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
NCT#03712605
Eligible for screening study DCP 001
EA6174 is temporarily closed to accrual, effective March 31, 2023.
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
Status:
Open
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
NCT#04511013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Status:
Open
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
NCT#04871542
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
Status:
Open
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) – A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study
NCT#05136196
S2101 will temporarily close to accrual on June 7, 2023, effective at 12:00pm Pacific Time.
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Solid tumor or Hematologic Malignancy
Status:
Open
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Eligible for screening study DCP 001
NCT#04438382
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Status:
Open
Blinded Reference Set For Multicancer Early Detection Blood Tests
NCT#05334069
A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Multiple Myeloma, Neuroendocrine, Non-Hodgkin Lymphoma, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT#05564377
Eligible for screening study DCP 001
Primary Category:
Treatment Protocols
Disease Category:
Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic
Status:
New, Open
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
NCT#05554380
(See required screening study ECOG-ACRIN EAY191)
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Open
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
NCT#05455606